Welcome to the CEO Roundtable on Cancer

Gold Standard Advancing to Reflect Latest Oncology Research

Oncology is perhaps the world’s fastest-moving therapeutic area. That requires the CEO Cancer Gold Standard™ framework -- a roadmap for building healthier communities at work and play -- to change with the science too. The Gold Standard requirements have been updated over the past year to reflect a more holistic approach to health and well-being with increased emphasis on cancer survivorship, well-being, and health equity.

Learn more
PDS Research Represented at ASCO

The American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8), one of the largest scientific gatherings in cancer research, will feature several abstracts related to Project Data Sphere® research programs on External Control Arms and Immune-related Adverse Events.

Learn more
Gold Standard companies growing healthy communities

Health equity is the goal for every person to be as healthy as possible regardless of their circumstance or background. There are many obstacles to achieving this goal, most of them non-medical: 50% are social factors, 30% health behaviors, and 20% medical care.

A top priority for the CEO Roundtable on Cancer in 2021 and beyond is advancing health equity in all that we do: Cancer Gold Standard™ health and wellbeing programs, Project Data Sphere™ clinical trial innovation programs, and a new Going for Gold initiative building partnerships with Historically Black Colleges and Universities and Hispanic Serving Institutions across the country.

Read more
Data platform boosts publications, research, advances in treatment

Project Data Sphere’s open access data platform has achieved a major milestone: Boosting the impact of oncology research by contributing to publication of more than 100 peer-reviewed articles that impact research and clinical practice.

“Secondary analysis of patient-level data is valuable,” said Bill Louv, President of PDS. “Analyzing the combined datasets increases statistical power to learn more about standard-of-care outcomes, rare adverse events, treatment effects in patient subsets, and reproducibility of results. That’s not possible with single datasets.”

Learn more

Our Mission

The mission of the CEO Roundtable on Cancer is to make continual progress toward the elimination of cancer as a personal disease and public health problem through initiatives that reduce the risk of cancer, enable early diagnosis, facilitate access to treatment, and hasten the discovery of effective therapies.

Workplace Wellness

A workplace wellness accreditation program designed to encourage healthy behaviors and improve health outcomes for employees by promoting prevention measures, encouraging early detection through cancer screenings, and ensuring access to quality care.

Research Innovation

Life sciences initiatives that bring together oncology, biotechnology and pharmaceutical companies to collaborate on removing obstacles and finding new ways to accelerate discovery and development of new therapies for cancer patients.

Global Cancer Control

Programs that catalyze progress in employee health at a global level and provide an environment that enables the compilation of historical oncology clinical trial data that will open new avenues of research.

FDA-PDS Symposium X on Sept. 23 to focus on data sharing

Mark your calendar for Symposium X to be held online from Noon until 3 pm EDT on September 23. Our planning group is excited to use this forum to generate new ways to think about clinical trial data reuse.

Learn more

GOLD STANDARD FRAMEWORK GETTING AN UPDATE

Re-accreditation for the CEO Cancer Gold Standard™, our employer-led health and wellness accreditation program, will be waived for 2021 as employers work even harder to focus on the health and well-being of their employees while also enforcing COVID-19 precautions.

This also gives us additional time to update our tools, resources and processes so we can continue to help you address the cancer burden and together create solutions for ending cancer.

Learn more